[go: up one dir, main page]

MX2012002172A - Anticuerpos contra el extodominio de erbb3 y usos de los mismos. - Google Patents

Anticuerpos contra el extodominio de erbb3 y usos de los mismos.

Info

Publication number
MX2012002172A
MX2012002172A MX2012002172A MX2012002172A MX2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A
Authority
MX
Mexico
Prior art keywords
erbb3
antibodies
receptor
antigen binding
binding fragments
Prior art date
Application number
MX2012002172A
Other languages
English (en)
Other versions
MX336091B (es
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002172(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MX2012002172A publication Critical patent/MX2012002172A/es
Publication of MX336091B publication Critical patent/MX336091B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una nueva clase de anticuerpos y fragmentos de unión a antígeno de los mismos que se unen al dominio extracelular del receptor ErbB3 e inhiben diversas funciones de ErbB3. Por ejemplo, los anticuerpos y fragmentos de unión a antígeno descritos en la presente son capaces de unirse al receptor designado ErbB3 e inhibir la fosforilación mediada por ligando similar a EGF del receptor. Dichos anticuerpos y fragmentos de unión a antígeno de los mismos tiene la característica útil de inhibir la proliferación de células cancerígenas que expresan ErbB3.
MX2012002172A 2009-08-21 2010-08-23 Anticuerpos contra el extodominio de erbb3 y usos de los mismos. MX336091B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Publications (2)

Publication Number Publication Date
MX2012002172A true MX2012002172A (es) 2012-05-29
MX336091B MX336091B (es) 2016-01-08

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002172A MX336091B (es) 2009-08-21 2010-08-23 Anticuerpos contra el extodominio de erbb3 y usos de los mismos.

Country Status (21)

Country Link
EP (1) EP2467164A2 (es)
JP (1) JP5752687B2 (es)
KR (1) KR20120059568A (es)
CN (1) CN103002912A (es)
AU (1) AU2010284018C1 (es)
BR (1) BR112012003809A2 (es)
CA (1) CA2771744A1 (es)
CR (1) CR20120108A (es)
DO (1) DOP2012000044A (es)
EA (1) EA201200195A1 (es)
EC (1) ECSP12011740A (es)
IL (1) IL218097A0 (es)
IN (1) IN2012DN01518A (es)
MA (1) MA33582B1 (es)
MX (1) MX336091B (es)
NI (1) NI201200027A (es)
PE (1) PE20121585A1 (es)
SG (1) SG178509A1 (es)
TN (1) TN2012000057A1 (es)
WO (1) WO2011022727A2 (es)
ZA (1) ZA201201195B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631727T3 (es) 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
CN105999263B (zh) * 2009-11-13 2021-06-29 第一三共欧洲有限公司 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
CN102822201B (zh) 2009-12-22 2014-09-24 罗切格利卡特公司 抗her3抗体及其用途
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
MX348637B (es) 2010-11-01 2017-06-22 Symphogen As Anticuerpos y composiciones anti-her3.
KR101517320B1 (ko) 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
CN103959065B (zh) 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
EP2788377B1 (en) * 2011-11-09 2019-01-23 The UAB Research Foundation Her3 antibodies and uses thereof
WO2013084147A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
WO2013124297A1 (en) * 2012-02-22 2013-08-29 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
EP3365373B1 (en) 2015-10-23 2021-03-10 Merus N.V. Binding molecules that inhibit cancer growth
KR102905513B1 (ko) 2017-03-31 2026-01-02 메뤼스 엔.페. NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
FI3665198T3 (fi) 2017-08-09 2025-04-25 Merus Nv EGFR:ää ja cMET:tä sitovia vasta-aineita
EP3665200B1 (en) 2017-08-09 2025-04-16 University of Saskatchewan Her3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
KR20230086702A (ko) * 2020-10-14 2023-06-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-her3 항체 및 항-her3 항체-약물 접합체 및 이의 의학적 용도
EP4247430A4 (en) * 2020-11-20 2024-12-11 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
AU2022293634A1 (en) * 2021-06-15 2024-01-18 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
CN119013307A (zh) * 2022-04-13 2024-11-22 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631727T3 (es) * 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos

Also Published As

Publication number Publication date
IL218097A0 (en) 2012-04-30
ZA201201195B (en) 2015-07-29
MX336091B (es) 2016-01-08
CA2771744A1 (en) 2011-02-24
ECSP12011740A (es) 2013-02-28
EP2467164A2 (en) 2012-06-27
KR20120059568A (ko) 2012-06-08
EA201200195A1 (ru) 2012-12-28
JP5752687B2 (ja) 2015-07-22
BR112012003809A2 (pt) 2019-09-24
WO2011022727A3 (en) 2013-06-27
AU2010284018A1 (en) 2012-03-22
MA33582B1 (fr) 2012-09-01
AU2010284018C1 (en) 2015-10-15
CR20120108A (es) 2012-06-05
CN103002912A (zh) 2013-03-27
WO2011022727A2 (en) 2011-02-24
PE20121585A1 (es) 2012-11-29
AU2010284018B2 (en) 2014-06-05
SG178509A1 (en) 2012-04-27
NI201200027A (es) 2013-01-29
DOP2012000044A (es) 2012-06-30
TN2012000057A1 (en) 2013-09-19
JP2013506622A (ja) 2013-02-28
IN2012DN01518A (es) 2015-06-05

Similar Documents

Publication Publication Date Title
TN2012000057A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
MX2009008656A (es) Anticuerpos contra erbb3 y usos de los mismos.
PH12019501115A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
PH12015500390A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX2014014951A (es) Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
CY1122978T1 (el) Αντισωματα εναντι-vla-4
MX366223B (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
PH12012501157A1 (en) Anti-her3 antibodies and uses thereof
MX348637B (es) Anticuerpos y composiciones anti-her3.
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
MX375439B (es) Moleculas de union cd37 y sus inmunoconjugados.
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
EP2331136A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
MX2014012843A (es) Anticuerpos anti-pdgf-c.
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
IN2014CN04374A (es)
WO2015048008A3 (en) Binding molecules specific for her3 and uses thereof
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
HK1166273A (en) Antibodies against the ectodomain of erbb3 and uses thereof
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.